AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Transgene Announces Financial Calendar for 2021

December 17, 2020 GMT

STRASBOURG, France--(BUSINESS WIRE)--Dec 17, 2020--

Regulatory News

Transgene (Paris:TNG) today announced its financial reporting dates for 2021:

March 10, 2021:

2020 Fiscal Year Results

 

 

April 27, 2021:

First Quarter 2021 Financial Results

 

 

May 26, 2021:

Annual Shareholders' Meeting

 

 

September 22, 2021:

First Half 2021 Financial Results

 

 

November 4, 2021:

Third Quarter 2021 Financial Results

About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac ® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).

ADVERTISEMENT

With Transgene’s myvac ® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac ® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at: www.transgene.fr
Follow us on Twitter: @TransgeneSA

View source version on businesswire.com:https://www.businesswire.com/news/home/20201217005732/en/

ADVERTISEMENT

CONTACT: Transgene:

Jean-Philippe Del/Lucie Larguier

+33 (0)3 88 27 91 04

investorrelations@transgene.fr Media contacts:

Citigate Dewe Rogerson

David Dible/Sylvie Berrebi

+44 (0)20 7638 9571

transgene@citigatedewerogerson.com

KEYWORD: FRANCE EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL ONCOLOGY

SOURCE: Transgene

Copyright Business Wire 2020.

PUB: 12/17/2020 11:45 AM/DISC: 12/17/2020 11:45 AM

http://www.businesswire.com/news/home/20201217005732/en